Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
What's the purpose of the trial?
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C39.033954%2C-94.615258%7C38.032398%2C-78.499001%7C41.894501%2C-87.621803%7C37.55376%2C-77.46026%7C34.061401%2C-118.205002%7C35.479801%2C-97.499802%7C33.634416%2C-117.921536%7C33.788101%2C-117.889999%7C36.0896%2C-80.2686%7C33.610291%2C-117.709938%7C40.879956%2C-73.879973%7C41.7883%2C-87.604599%7C41.543229%2C-87.984693%7C41.630881%2C-87.854592%7C35.903011%2C-79.053528%7C40.772598%2C-111.834%7C38.554298%2C-121.452003%7C41.304827%2C-72.935904%7C30.2628%2C-81.441299)
Participating Centers
There are 19 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Inqovi is an oral chemotherapy medication. It combines two different drugs, decitabine, which is a hypomethylating chemotherapy agent, and cedazuridine, which is a CDA inhibitor that helps decitabine to work effectively in the body.
- Venetoclax is a BCL-2 inhibitor that may work by blocking the action of the BCL-2 protein on some cancer cells which can lead to cell death.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.